Type: Oral
Session: 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Know Thy(mus) Self, Know Thy Enemy: From Lymphocyte Genetic Variation to Disease
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Viral, Genetic Disorders, Diseases, Infectious Diseases
METHODS: To investigate the role of recurrent TNFRSF13B variants in the process of EBV infection and immortalization, B lymphoblastoid cell lines (B-LCL) models carrying homozygous TNFRSF13B exon 2 frameshift deletions/insertions was successfully constructed using the CRISPR/Cas9 technique. Several examinations are performed to clarify the influences of TACI variants in EBV-infected B cells, including the TACI expression, cell viability, B-lineage immunophenotype, the activation of downstream signaling pathways, the EBV lytic replication/latency program, and the secretion of cytokines. To verify the potentials of TNFRSF13B-targeting therapy in EBV-LPDs, drugs that regulate TACI expression or the TACI-mediated signaling were applied in B-LCL models. Finally, the possible mechanisms of TACI-mediated EBV reactivation in the immortalized B cells were investigated primarily through transcriptomic analysis and subsequent validation experiments.
RESULTS: In the cohort of previous research, six non-primary EBV-T/NK-LPD patients carry rare heterozygous pathogenic germline TNFRSF13B variants, of which 5 mutations were located at the exon 2 of this gene. Introducing frameshift deletions/insertions at the exon 2 of TNFRSF13B in healthy donor-derived B-LCLs diminished the expression of long isoforms of TACI (TACI-L) but significantly upregulated the short isoforms of TACI (TACI-S). The enhanced expression of TACI-S delivered more intense activation of NF-κB, MAPK, Rho, and PI3K/AKT pathways, induced the reactivation of EBV lytic replication in LCLs, promoted the secretion of viral interleukin (IL)-10 and pro-inflammatory cytokines, ultimately led to the significantly increased EBV loads, rendering the carriers susceptible to EBV-LPDs. Furthermore, the low-affinity 3-mer forms of TACI ligand, B cell-activating factor (BAFF), and a proliferation-inducing ligand (APRIL) significantly reduced TACI signaling, suppressing the EBV lytic program, and thus alleviating the EBV infection in B-LCLs. The AKT signaling suppressor TUSC3 differently expressed in TACI exon 2 variant-expressing and wild-type B-LCLs, might mediate the TACI-associated EBV lytic reactivation.
CONCLUSIONS: This research proposes that the TNFRSF13B variants play important roles during the process of EBV-LPD development by regulating the expression of TACI isoforms. For patients who carry the gain-of-function germline mutations of TNFRSF13B, the inhibitory TACI-Ig or the TACI ligands BAFF and APRIL may efficiently prevent the serious progression of their EBV infection. Screening for possibly pathogenic variants, especially in the TNF-TNFR superfamily genes in EBV-LPD patients is necessary and valuable for understanding the pathogenesis of EBV-LPDs and optimizing the therapeutic regimen.
Disclosures: No relevant conflicts of interest to declare.